In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Merz gains Radiesse wrinkle filler

This article was originally published in The Rose Sheet

Executive Summary

German drug company's $253 mil. acquisition of California-based BioForm Medical, announced Jan. 4, provides it with latter's FDA-approved Radiesse wrinkle filler, rounding out its aesthetic product offering and accentuating its presence in the U.S. Merz's pre-acquisition aesthetic portfolio included dermal fillers Belotero (hyaluronic acid) and Novabel (alginate), both available in Europe and undergoing trials to support U.S. approval. Sales of Mederma anti-scarring creams have helped support the firm's U.S. business (1"The Rose Sheet" July 20, 2009). Made of smooth calcium hydroxylapatite microspheres suspended in a gel and designed to stimulate production of new collagen as a patient's own soft tissue replaces the gel carrier, Radiesse competes against Allergan's Juvederm, Medicis' Restylane and Johnson & Johnson's Evolence, among others. BioForm booked sales of about $66.5 mil. in fiscal 2009. Following completion of the acquisition, which Merz expects in March, the firm will relocate its U.S. aesthetics business to BioForm's San Mateo, Calif., headquarters and the combined operation will be renamed Merz Aesthetics

You may also be interested in...

Mederma Anti-Scarring Targets Stretch Marks With New Cream

Merz Pharmaceuticals is launching its newest Mederma cream with a specific type of scarring in its crosshairs - striae, or stretch marks

Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza

The latest drug development news and highlights from our US FDA Performance Tracker.

Epizyme’s Tazverik Gets To Market In Rare Sarcoma, Paving Way To Bigger Indications

Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts